BIOMAT Database Logo BIOMAT Database Logo

[Myasthenia gravis (3). Corticosteroid therapy of myasthenia gravis]. 1978

G Matell, and P O Osterman

UI MeSH Term Description Entries
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D006680 HLA Antigens Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases. Human Leukocyte Antigen,Human Leukocyte Antigens,Leukocyte Antigens,HL-A Antigens,Antigen, Human Leukocyte,Antigens, HL-A,Antigens, HLA,Antigens, Human Leukocyte,Antigens, Leukocyte,HL A Antigens,Leukocyte Antigen, Human,Leukocyte Antigens, Human
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

G Matell, and P O Osterman
[Corticosteroid therapy combined with thymectomy in myasthenia gravis].
April 1983, Rinsho shinkeigaku = Clinical neurology,
G Matell, and P O Osterman
Cellular immunity in myasthenia gravis after thymectomy and corticosteroid therapy.
January 1990, Japanese journal of medicine,
G Matell, and P O Osterman
Oral corticosteroid therapy and present disease status in myasthenia gravis.
May 2015, Muscle & nerve,
G Matell, and P O Osterman
Corticosteroid Treatment-Resistance in Myasthenia Gravis.
January 2022, Frontiers in neurology,
G Matell, and P O Osterman
Long-term results of corticosteroid therapy in patients with myasthenia gravis.
January 1992, European neurology,
G Matell, and P O Osterman
Long-term corticosteroid treatment of myasthenia gravis.
January 1987, Annals of the New York Academy of Sciences,
G Matell, and P O Osterman
Severe occult juvenile myasthenia gravis responsive to long-term corticosteroid therapy.
January 1968, Transactions of the American Neurological Association,
G Matell, and P O Osterman
Corticosteroid-induced mediastinal widening in myasthenia gravis.
October 1975, Archives of neurology,
G Matell, and P O Osterman
Etanercept treatment in corticosteroid-dependent myasthenia gravis.
December 2004, Neurology,
G Matell, and P O Osterman
[Myasthenia gravis. Therapy].
February 1977, Revista clinica espanola,
Copied contents to your clipboard!